title: [Targeted therapies in pediatric oncology: a new therapeutic approach?].
abstract: A multidisciplinary therapeutic approach has led to significant increase in survival of children with cancer, however often with a high rate of severe sequela. Better understanding in tumor cell biology and transformation process allowed to describe active tyrosine kinases (mainly growth factor receptors) as a new target for cancer treatment. This review presents 2 approaches to target receptor tyrosine kinase activity: on one hand, antibodies that target the extracellular domain, the natural ligand binding site, and on the other hand, small inhibiting molecules, such as imatinib, targeted against the activated intracellular receptor tyrosine kinase. We focus on their clinical development and current application in the treatment of childhood cancer. Targeted therapies are in full rise and new perspectives are explored, such as their association to other treatment modalities and the targeting of microenvironment. This new therapeutic approach necessitates well designed clinical trials that include relevant biomarkers to evaluate its real therapeutic potential.
authors.affiliation: UPRES EA 3535, Département de Pédiatrie, Pharmacologie et Nouveaux Traitements des Cancers, Institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif cedex, France.
authors.forename: C
authors.initials: C
authors.lastname: Jubert
authors.forename: B
authors.initials: B
authors.lastname: Geoerger
authors.forename: J
authors.initials: J
authors.lastname: Grill
authors.forename: O
authors.initials: O
authors.lastname: Hartmann
authors.forename: G
authors.initials: G
authors.lastname: Vassal
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides; D002648:Child; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D000068877:Imatinib Mesylate; D009369:Neoplasms / Q000188:drug therapy; D010879:Piperazines / Q000494:pharmacology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000494:pharmacology; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases